(S)-Tedizolid

"目录号: HY-14855B

Anti-infection-

Torezolid磷酸盐是MAO-A和MAO-B抑制剂,具有抗革兰氏阳性菌的活性。

Bacterial

相关产品

G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tedizolid-

生物活性

Description

Tedizolid phosphate is a novel oxazolidinone with activity against Gram-positive pathogens.

In Vitro

Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP, and is 4-fold more potent than linezolid against PRSP[1].

In Vivo

For mice infected with PSSP type III, the 100% survival rate is achieved with tedizolid phosphate at a minimum total daily dose of 10 mg/kg. Lungs of infected mice treated with tedizolid phosphate show less severe inflammation and edema, as indicated by the mean scores for inflammation and edema[1].

Clinical Trial

NCT03009045

Los Angeles Biomedical Research Institute

Bone and Joint Infection

February 6, 2017

Phase 2

NCT02342418

Amit.Pai-Merck Sharp & Dohme Corp.-Albany College of Pharmacy and Health Sciences

Obesity

March 2015

Phase 4

NCT02620787

Hartford Hospital-Merck Sharp & Dohme Corp.

Diabetes-Wound Infection-Healthy Volunteers

February 23, 2016

Phase 1

NCT03217565

Merck Sharp & Dohme Corp.

Gram-Positive Infections

March 5, 2018

Phase 1

NCT02444234

University of Southern California-Merck Sharp & Dohme Corp.

Cystic Fibrosis

July 2015

Phase 4

NCT02750761

Merck Sharp & Dohme Corp.

Gram-Positive Bacterial Infections

May 2, 2016

Phase 1

NCT02276482

Cubist Pharmaceuticals LLC

Skin Diseases, Infectious-Skin Diseases, Bacterial

March 25, 2015

Phase 3

NCT02991131

Bayer

Abscess-Cellulitis-Erysipelas-Wound Infection

January 13, 2017

NCT02066402

Bayer-Merck Sharp & Dohme Corp.

Bacterial Infections

March 4, 2014

Phase 3

NCT02019420

Cubist Pharmaceuticals LLC

Pneumonia

January 6, 2014

Phase 3

NCT02477514

Merck Sharp & Dohme Corp.

Skin Diseases, Bacterial

June 2015

Phase 1

NCT01967225

Bayer

Skin Diseases, Infectious

November 2013

Phase 3

NCT00666601

Trius Therapeutics LLC

Healthy

April 2008

Phase 1

View MoreCollapse

References

[1].Choi S, et al. Activity of Tedizolid Phosphate (TR-701) in Murine Models of Infection with Penicillin-resistant and Penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother. 2012 Jun 19.

你可能感兴趣的:((S)-Tedizolid)